Kurse werden geladen...
Prognose
Für dieses Unternehmen liegen uns keine Analysten-Daten vor.
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
Beliebteste Broker
News
16.04. - 13:52 Uhr
BioHarvest Sciences unveils new state-of-the-art campus
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) announced that it has signed two agreements to create a new campus for its botanical synthesis contract development and manufacturing organization (CDMO) business unit in Yavne, Israel. The biotechnology firm, which is advancing its patented Botanical Synthesis process, said it has signed an agreement for the purchase of 12 state-of-the-art GMP clean rooms and a second agreement for the long-term lease of an 80,000-square-foot facility. » Mehr auf proactiveinvestors.com
21.03. - 13:13 Uhr
BioHarvest Sciences appoints experienced life sciences exec to VP role
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) announced that it has appointed experienced life sciences executive Anna Tenstam to the role of VP of Business Development, Cosmeceuticals and Injectables to propel the expansion of its recently launched Contract Development and Manufacturing Organization (CDMO) services business unit. The company said that Tenstam brings more than 30 years of leadership experience with pharmaceutical, medical devices and medical aesthetics companies worldwide to the position. » Mehr auf proactiveinvestors.com
13.03. - 14:32 Uhr
BioHarvest Sciences appoints senior leaders to CDMO unit
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF), the biotechnology company, has appointed two senior hires for its recently launched CDMO services business unit. Matt Zrebiec will join the unit as vice president of business development and will look to source and close new deals for the new division. » Mehr auf proactiveinvestors.com
Historische Dividenden
Alle Dividenden KennzahlenUnternehmenszahlen
| (EUR) | Sep. 2023 | |
|---|---|---|
| Umsatz | 3,02 Mio | - |
| Bruttoeinkommen | 1,14 Mio | - |
| Nettoeinkommen | 1,61 Mio | - |
| EBITDA | 1,67 Mio | - |
Fundamentaldaten
| Metrik | Wert |
|---|---|
Marktkapitalisierung | 85,27 Mio € |
Anzahl Aktien | 478,69 Mio |
52 Wochen-Hoch/Tief | 0,21 € - 0,11 € |
Dividendenrendite | 274,57 % |
Dividenden TTM | 0,47 € |
Beta | 1,46 |
KGV (PE Ratio) | 10,95 |
KGWV (PEG Ratio) | 1,24 |
KBV (PB Ratio) | 11,57 |
KUV (PS Ratio) | 8,59 |
Unternehmensprofil
BioHarvest Sciences Inc. bietet zusammen mit seinen Tochtergesellschaften in Israel und auf internationaler Ebene Superfrüchte und Cannabisprodukte an. Seine Technologie zur Züchtung von Pflanzenzellen produziert die aktiven Sekundärmetaboliten, ohne dass die Pflanze selbst gezüchtet werden muss. Das Unternehmen entwirft, entwickelt, produziert und vermarktet Vinia, ein nutrazeutisches Produkt aus rotem Traubenpulver, sowie medizinisches Cannabis. BioHarvest Sciences Inc. hat seinen Sitz in Vancouver, Kanada.
| Name | BIOHARVEST SCIENCES INC |
| CEO | Ilan Sobel |
| Sitz | Vancouver,
bc Israel |
| Website | |
| Industrie | Biotechnologie |
| Börsengang | 08.01.2021 |
| Mitarbeiter | 0 |
Ticker Symbole
| Börse | Symbol |
|---|---|
Pnk | CNVCF |
Frankfurt | 8MV.F |
München | 8MV.MU |
Nse | DREAMFOLKS.NS |
Assets entdecken
Shareholder von BIOHARVEST SCIENCES INC investieren auch in folgende Assets
-
-
-
-
-
-
-
-
-
-